Erasca, Inc. (NASDAQ:ERAS) Q4 2023 Earnings Call Transcript

Operator: Our next question comes from the line of Andres Maldonado with HC. Wainwright.

Andres Maldonado: Hi guys. Congrats on the progress, and thanks for sneaking me in here. So maybe a follow-up to the last question. How should we be thinking about the synergistic contribution to OS between Napo and tremendous in the context of the efficacy being driven more by BRAF and CRAF being hit Or is it being driven more by true net new unique ability to break mathematics complexes and obviously that has implications to the tissue types in RAS Q61 where maybe melanomas far more heavily reliant on. We’re breaking the complex as any broad thoughts there on how we should balance the synergistic contribution between the two arms?

Jonathan Lim: Yes, thanks. I think at this point, it’s probably really difficult to tell the individual contributions, which is why we think Stage 1 will give us some info in terms of trametinib single agent at that 2 milligram dose versus two different combos. So there is definitely a synergy. It’s probably roughly similar contributions. But I guess that’s the benefit of synergy. Is that the one plus one equals three, right? So I think in some ways, it almost doesn’t matter as long as you’re seeing synergy.

Operator: Thank you. We have reached the end of our question-and-answer session. And with that, that does conclude today’s teleconference. We appreciate your participation. You may disconnect your lines at this time and enjoy the rest of your day.